0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative

0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Human Recombinant Insulin Market Research Report 2025
Published Date: July 2025
|
Report Code: QYRE-Auto-30M1041
Home | Market Reports | Business & Industrial| Pharmaceuticals & Biotech
Global Human Recombinant Insulin Market Insights and Forecast to 2028
BUY CHAPTERS

Global Human Recombinant Insulin Market Research Report 2025

Code: QYRE-Auto-30M1041
Report
July 2025
Pages:91
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES

Human Recombinant Insulin Market

The global market for Human Recombinant Insulin was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.
Insulin decreases blood glucose concentration. It increases cell permeability to monosaccharides, amino acids and fatty acids. It accelerates glycolysis, the pentose phosphate cycle, and glycogen synthesis in liver.Recombinant human insulin has a significant advantage over insulin from other animal sources. Patients can better absorb human insulin.It is also easier to manage allergies related to insulin intake.
North American market for Human Recombinant Insulin is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for Human Recombinant Insulin is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The major global manufacturers of Human Recombinant Insulin include Novo Nordisk, Eli Lilly and Company, Sanofi, Julphar Gulf Pharmaceutical Industries, Bioton, Gan & Lee Pharmaceuticals, Zhuhai United Laboratories, Biocon, Wanbang Biopharmaceuticals, Dongbao Enterprise Group, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Human Recombinant Insulin, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Human Recombinant Insulin.
The Human Recombinant Insulin market size, estimations, and forecasts are provided in terms of sales volume (K Litre) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Human Recombinant Insulin market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Human Recombinant Insulin manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Scope of Human Recombinant Insulin Market Report

Report Metric Details
Report Name Human Recombinant Insulin Market
Segment by Type
  • Rapid-Acting Human Insulin
  • Regular (Short Acting) Insulin
  • NPH (Intermediate Acting) Insulin
  • Long-Acting Human Insulin
  • Premixed Human Insulins Insulin
Segment by Application
  • Hospital
  • Retail Pharmacy
  • Online Pharmacies
  • Other
Consumption by Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia)
  • Asia-Pacific (China, Japan, South Korea, Taiwan)
  • Southeast Asia (India)
  • Latin America (Mexico, Brazil)
By Company Novo Nordisk, Eli Lilly and Company, Sanofi, Julphar Gulf Pharmaceutical Industries, Bioton, Gan & Lee Pharmaceuticals, Zhuhai United Laboratories, Biocon, Wanbang Biopharmaceuticals, Dongbao Enterprise Group, PeproTech
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Core Chapters

  • Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
  • Chapter 2: Detailed analysis of Human Recombinant Insulin manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
  • Chapter 3: Sales, revenue of Human Recombinant Insulin in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
  • Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
  • Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
  • Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
  • Chapter 9: The main points and conclusions of the report. 

FAQ for this report

Who are the main players in the Human Recombinant Insulin Market report?

Ans: The main players in the Human Recombinant Insulin Market are Novo Nordisk, Eli Lilly and Company, Sanofi, Julphar Gulf Pharmaceutical Industries, Bioton, Gan & Lee Pharmaceuticals, Zhuhai United Laboratories, Biocon, Wanbang Biopharmaceuticals, Dongbao Enterprise Group, PeproTech

What are the Application segmentation covered in the Human Recombinant Insulin Market report?

Ans: The Applications covered in the Human Recombinant Insulin Market report are Hospital, Retail Pharmacy, Online Pharmacies, Other

What are the Type segmentation covered in the Human Recombinant Insulin Market report?

Ans: The Types covered in the Human Recombinant Insulin Market report are Rapid-Acting Human Insulin, Regular (Short Acting) Insulin, NPH (Intermediate Acting) Insulin, Long-Acting Human Insulin, Premixed Human Insulins Insulin

1 Human Recombinant Insulin Market Overview
1.1 Product Definition
1.2 Human Recombinant Insulin by Type
1.2.1 Global Human Recombinant Insulin Market Value Comparison by Type (2024 VS 2031)
1.2.2 Rapid-Acting Human Insulin
1.2.3 Regular (Short Acting) Insulin
1.2.4 NPH (Intermediate Acting) Insulin
1.2.5 Long-Acting Human Insulin
1.2.6 Premixed Human Insulins Insulin
1.3 Human Recombinant Insulin by Application
1.3.1 Global Human Recombinant Insulin Market Value by Application (2024 VS 2031)
1.3.2 Hospital
1.3.3 Retail Pharmacy
1.3.4 Online Pharmacies
1.3.5 Other
1.4 Global Human Recombinant Insulin Market Size Estimates and Forecasts
1.4.1 Global Human Recombinant Insulin Revenue 2020-2031
1.4.2 Global Human Recombinant Insulin Sales 2020-2031
1.4.3 Global Human Recombinant Insulin Market Average Price (2020-2031)
1.5 Assumptions and Limitations
2 Human Recombinant Insulin Market Competition by Manufacturers
2.1 Global Human Recombinant Insulin Sales Market Share by Manufacturers (2020-2025)
2.2 Global Human Recombinant Insulin Revenue Market Share by Manufacturers (2020-2025)
2.3 Global Human Recombinant Insulin Average Price by Manufacturers (2020-2025)
2.4 Global Key Players of Human Recombinant Insulin, Industry Ranking, 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Human Recombinant Insulin, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Human Recombinant Insulin, Product Type & Application
2.7 Global Key Manufacturers of Human Recombinant Insulin, Date of Enter into This Industry
2.8 Global Human Recombinant Insulin Market Competitive Situation and Trends
2.8.1 Global Human Recombinant Insulin Market Concentration Rate
2.8.2 The Global 5 and 10 Largest Human Recombinant Insulin Players Market Share by Revenue
2.8.3 Global Human Recombinant Insulin Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Human Recombinant Insulin Market Scenario by Region
3.1 Global Human Recombinant Insulin Market Size by Region: 2020 Versus 2024 Versus 2031
3.2 Global Human Recombinant Insulin Sales by Region: 2020-2031
3.2.1 Global Human Recombinant Insulin Sales by Region: 2020-2025
3.2.2 Global Human Recombinant Insulin Sales by Region: 2026-2031
3.3 Global Human Recombinant Insulin Revenue by Region: 2020-2031
3.3.1 Global Human Recombinant Insulin Revenue by Region: 2020-2025
3.3.2 Global Human Recombinant Insulin Revenue by Region: 2026-2031
3.4 North America Human Recombinant Insulin Market Facts & Figures by Country
3.4.1 North America Human Recombinant Insulin Market Size by Country: 2020 VS 2024 VS 2031
3.4.2 North America Human Recombinant Insulin Sales by Country (2020-2031)
3.4.3 North America Human Recombinant Insulin Revenue by Country (2020-2031)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Human Recombinant Insulin Market Facts & Figures by Country
3.5.1 Europe Human Recombinant Insulin Market Size by Country: 2020 VS 2024 VS 2031
3.5.2 Europe Human Recombinant Insulin Sales by Country (2020-2031)
3.5.3 Europe Human Recombinant Insulin Revenue by Country (2020-2031)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Human Recombinant Insulin Market Facts & Figures by Region
3.6.1 Asia Pacific Human Recombinant Insulin Market Size by Region: 2020 VS 2024 VS 2031
3.6.2 Asia Pacific Human Recombinant Insulin Sales by Region (2020-2031)
3.6.3 Asia Pacific Human Recombinant Insulin Revenue by Region (2020-2031)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America Human Recombinant Insulin Market Facts & Figures by Country
3.7.1 Latin America Human Recombinant Insulin Market Size by Country: 2020 VS 2024 VS 2031
3.7.2 Latin America Human Recombinant Insulin Sales by Country (2020-2031)
3.7.3 Latin America Human Recombinant Insulin Revenue by Country (2020-2031)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Human Recombinant Insulin Market Facts & Figures by Country
3.8.1 Middle East and Africa Human Recombinant Insulin Market Size by Country: 2020 VS 2024 VS 2031
3.8.2 Middle East and Africa Human Recombinant Insulin Sales by Country (2020-2031)
3.8.3 Middle East and Africa Human Recombinant Insulin Revenue by Country (2020-2031)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Human Recombinant Insulin Sales by Type (2020-2031)
4.1.1 Global Human Recombinant Insulin Sales by Type (2020-2025)
4.1.2 Global Human Recombinant Insulin Sales by Type (2026-2031)
4.1.3 Global Human Recombinant Insulin Sales Market Share by Type (2020-2031)
4.2 Global Human Recombinant Insulin Revenue by Type (2020-2031)
4.2.1 Global Human Recombinant Insulin Revenue by Type (2020-2025)
4.2.2 Global Human Recombinant Insulin Revenue by Type (2026-2031)
4.2.3 Global Human Recombinant Insulin Revenue Market Share by Type (2020-2031)
4.3 Global Human Recombinant Insulin Price by Type (2020-2031)
5 Segment by Application
5.1 Global Human Recombinant Insulin Sales by Application (2020-2031)
5.1.1 Global Human Recombinant Insulin Sales by Application (2020-2025)
5.1.2 Global Human Recombinant Insulin Sales by Application (2026-2031)
5.1.3 Global Human Recombinant Insulin Sales Market Share by Application (2020-2031)
5.2 Global Human Recombinant Insulin Revenue by Application (2020-2031)
5.2.1 Global Human Recombinant Insulin Revenue by Application (2020-2025)
5.2.2 Global Human Recombinant Insulin Revenue by Application (2026-2031)
5.2.3 Global Human Recombinant Insulin Revenue Market Share by Application (2020-2031)
5.3 Global Human Recombinant Insulin Price by Application (2020-2031)
6 Key Companies Profiled
6.1 Novo Nordisk
6.1.1 Novo Nordisk Company Information
6.1.2 Novo Nordisk Description and Business Overview
6.1.3 Novo Nordisk Human Recombinant Insulin Sales, Revenue and Gross Margin (2020-2025)
6.1.4 Novo Nordisk Human Recombinant Insulin Product Portfolio
6.1.5 Novo Nordisk Recent Developments/Updates
6.2 Eli Lilly and Company
6.2.1 Eli Lilly and Company Company Information
6.2.2 Eli Lilly and Company Description and Business Overview
6.2.3 Eli Lilly and Company Human Recombinant Insulin Sales, Revenue and Gross Margin (2020-2025)
6.2.4 Eli Lilly and Company Human Recombinant Insulin Product Portfolio
6.2.5 Eli Lilly and Company Recent Developments/Updates
6.3 Sanofi
6.3.1 Sanofi Company Information
6.3.2 Sanofi Description and Business Overview
6.3.3 Sanofi Human Recombinant Insulin Sales, Revenue and Gross Margin (2020-2025)
6.3.4 Sanofi Human Recombinant Insulin Product Portfolio
6.3.5 Sanofi Recent Developments/Updates
6.4 Julphar Gulf Pharmaceutical Industries
6.4.1 Julphar Gulf Pharmaceutical Industries Company Information
6.4.2 Julphar Gulf Pharmaceutical Industries Description and Business Overview
6.4.3 Julphar Gulf Pharmaceutical Industries Human Recombinant Insulin Sales, Revenue and Gross Margin (2020-2025)
6.4.4 Julphar Gulf Pharmaceutical Industries Human Recombinant Insulin Product Portfolio
6.4.5 Julphar Gulf Pharmaceutical Industries Recent Developments/Updates
6.5 Bioton
6.5.1 Bioton Company Information
6.5.2 Bioton Description and Business Overview
6.5.3 Bioton Human Recombinant Insulin Sales, Revenue and Gross Margin (2020-2025)
6.5.4 Bioton Human Recombinant Insulin Product Portfolio
6.5.5 Bioton Recent Developments/Updates
6.6 Gan & Lee Pharmaceuticals
6.6.1 Gan & Lee Pharmaceuticals Company Information
6.6.2 Gan & Lee Pharmaceuticals Description and Business Overview
6.6.3 Gan & Lee Pharmaceuticals Human Recombinant Insulin Sales, Revenue and Gross Margin (2020-2025)
6.6.4 Gan & Lee Pharmaceuticals Human Recombinant Insulin Product Portfolio
6.6.5 Gan & Lee Pharmaceuticals Recent Developments/Updates
6.7 Zhuhai United Laboratories
6.7.1 Zhuhai United Laboratories Company Information
6.7.2 Zhuhai United Laboratories Description and Business Overview
6.7.3 Zhuhai United Laboratories Human Recombinant Insulin Sales, Revenue and Gross Margin (2020-2025)
6.7.4 Zhuhai United Laboratories Human Recombinant Insulin Product Portfolio
6.7.5 Zhuhai United Laboratories Recent Developments/Updates
6.8 Biocon
6.8.1 Biocon Company Information
6.8.2 Biocon Description and Business Overview
6.8.3 Biocon Human Recombinant Insulin Sales, Revenue and Gross Margin (2020-2025)
6.8.4 Biocon Human Recombinant Insulin Product Portfolio
6.8.5 Biocon Recent Developments/Updates
6.9 Wanbang Biopharmaceuticals
6.9.1 Wanbang Biopharmaceuticals Company Information
6.9.2 Wanbang Biopharmaceuticals Description and Business Overview
6.9.3 Wanbang Biopharmaceuticals Human Recombinant Insulin Sales, Revenue and Gross Margin (2020-2025)
6.9.4 Wanbang Biopharmaceuticals Human Recombinant Insulin Product Portfolio
6.9.5 Wanbang Biopharmaceuticals Recent Developments/Updates
6.10 Dongbao Enterprise Group
6.10.1 Dongbao Enterprise Group Company Information
6.10.2 Dongbao Enterprise Group Description and Business Overview
6.10.3 Dongbao Enterprise Group Human Recombinant Insulin Sales, Revenue and Gross Margin (2020-2025)
6.10.4 Dongbao Enterprise Group Human Recombinant Insulin Product Portfolio
6.10.5 Dongbao Enterprise Group Recent Developments/Updates
6.11 PeproTech
6.11.1 PeproTech Company Information
6.11.2 PeproTech Description and Business Overview
6.11.3 PeproTech Human Recombinant Insulin Sales, Revenue and Gross Margin (2020-2025)
6.11.4 PeproTech Human Recombinant Insulin Product Portfolio
6.11.5 PeproTech Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Human Recombinant Insulin Industry Chain Analysis
7.2 Human Recombinant Insulin Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Human Recombinant Insulin Production Mode & Process Analysis
7.4 Human Recombinant Insulin Sales and Marketing
7.4.1 Human Recombinant Insulin Sales Channels
7.4.2 Human Recombinant Insulin Distributors
7.5 Human Recombinant Insulin Customer Analysis
8 Human Recombinant Insulin Market Dynamics
8.1 Human Recombinant Insulin Industry Trends
8.2 Human Recombinant Insulin Market Drivers
8.3 Human Recombinant Insulin Market Challenges
8.4 Human Recombinant Insulin Market Restraints
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
List of Tables
 Table 1. Global Human Recombinant Insulin Market Value Comparison by Type (2024 VS 2031) & (US$ Million)
 Table 2. Global Human Recombinant Insulin Market Value by Application (2024 VS 2031) & (US$ Million)
 Table 3. Global Human Recombinant Insulin Market Competitive Situation by Manufacturers in 2024
 Table 4. Global Human Recombinant Insulin Sales (K Litre) of Key Manufacturers (2020-2025)
 Table 5. Global Human Recombinant Insulin Sales Market Share by Manufacturers (2020-2025)
 Table 6. Global Human Recombinant Insulin Revenue (US$ Million) by Manufacturers (2020-2025)
 Table 7. Global Human Recombinant Insulin Revenue Share by Manufacturers (2020-2025)
 Table 8. Global Market Human Recombinant Insulin Average Price (USD/Litre) of Key Manufacturers (2020-2025)
 Table 9. Global Key Players of Human Recombinant Insulin, Industry Ranking, 2022 VS 2023 VS 2024
 Table 10. Global Key Manufacturers of Human Recombinant Insulin, Manufacturing Sites & Headquarters
 Table 11. Global Key Manufacturers of Human Recombinant Insulin, Product Type & Application
 Table 12. Global Key Manufacturers of Human Recombinant Insulin, Date of Enter into This Industry
 Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
 Table 14. Global Human Recombinant Insulin by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Human Recombinant Insulin as of 2024)
 Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
 Table 16. Global Human Recombinant Insulin Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Table 17. Global Human Recombinant Insulin Sales by Region (2020-2025) & (K Litre)
 Table 18. Global Human Recombinant Insulin Sales Market Share by Region (2020-2025)
 Table 19. Global Human Recombinant Insulin Sales by Region (2026-2031) & (K Litre)
 Table 20. Global Human Recombinant Insulin Sales Market Share by Region (2026-2031)
 Table 21. Global Human Recombinant Insulin Revenue by Region (2020-2025) & (US$ Million)
 Table 22. Global Human Recombinant Insulin Revenue Market Share by Region (2020-2025)
 Table 23. Global Human Recombinant Insulin Revenue by Region (2026-2031) & (US$ Million)
 Table 24. Global Human Recombinant Insulin Revenue Market Share by Region (2026-2031)
 Table 25. North America Human Recombinant Insulin Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 26. North America Human Recombinant Insulin Sales by Country (2020-2025) & (K Litre)
 Table 27. North America Human Recombinant Insulin Sales by Country (2026-2031) & (K Litre)
 Table 28. North America Human Recombinant Insulin Revenue by Country (2020-2025) & (US$ Million)
 Table 29. North America Human Recombinant Insulin Revenue by Country (2026-2031) & (US$ Million)
 Table 30. Europe Human Recombinant Insulin Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 31. Europe Human Recombinant Insulin Sales by Country (2020-2025) & (K Litre)
 Table 32. Europe Human Recombinant Insulin Sales by Country (2026-2031) & (K Litre)
 Table 33. Europe Human Recombinant Insulin Revenue by Country (2020-2025) & (US$ Million)
 Table 34. Europe Human Recombinant Insulin Revenue by Country (2026-2031) & (US$ Million)
 Table 35. Asia Pacific Human Recombinant Insulin Revenue by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Table 36. Asia Pacific Human Recombinant Insulin Sales by Region (2020-2025) & (K Litre)
 Table 37. Asia Pacific Human Recombinant Insulin Sales by Region (2026-2031) & (K Litre)
 Table 38. Asia Pacific Human Recombinant Insulin Revenue by Region (2020-2025) & (US$ Million)
 Table 39. Asia Pacific Human Recombinant Insulin Revenue by Region (2026-2031) & (US$ Million)
 Table 40. Latin America Human Recombinant Insulin Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 41. Latin America Human Recombinant Insulin Sales by Country (2020-2025) & (K Litre)
 Table 42. Latin America Human Recombinant Insulin Sales by Country (2026-2031) & (K Litre)
 Table 43. Latin America Human Recombinant Insulin Revenue by Country (2020-2025) & (US$ Million)
 Table 44. Latin America Human Recombinant Insulin Revenue by Country (2026-2031) & (US$ Million)
 Table 45. Middle East and Africa Human Recombinant Insulin Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 46. Middle East and Africa Human Recombinant Insulin Sales by Country (2020-2025) & (K Litre)
 Table 47. Middle East and Africa Human Recombinant Insulin Sales by Country (2026-2031) & (K Litre)
 Table 48. Middle East and Africa Human Recombinant Insulin Revenue by Country (2020-2025) & (US$ Million)
 Table 49. Middle East and Africa Human Recombinant Insulin Revenue by Country (2026-2031) & (US$ Million)
 Table 50. Global Human Recombinant Insulin Sales (K Litre) by Type (2020-2025)
 Table 51. Global Human Recombinant Insulin Sales (K Litre) by Type (2026-2031)
 Table 52. Global Human Recombinant Insulin Sales Market Share by Type (2020-2025)
 Table 53. Global Human Recombinant Insulin Sales Market Share by Type (2026-2031)
 Table 54. Global Human Recombinant Insulin Revenue (US$ Million) by Type (2020-2025)
 Table 55. Global Human Recombinant Insulin Revenue (US$ Million) by Type (2026-2031)
 Table 56. Global Human Recombinant Insulin Revenue Market Share by Type (2020-2025)
 Table 57. Global Human Recombinant Insulin Revenue Market Share by Type (2026-2031)
 Table 58. Global Human Recombinant Insulin Price (USD/Litre) by Type (2020-2025)
 Table 59. Global Human Recombinant Insulin Price (USD/Litre) by Type (2026-2031)
 Table 60. Global Human Recombinant Insulin Sales (K Litre) by Application (2020-2025)
 Table 61. Global Human Recombinant Insulin Sales (K Litre) by Application (2026-2031)
 Table 62. Global Human Recombinant Insulin Sales Market Share by Application (2020-2025)
 Table 63. Global Human Recombinant Insulin Sales Market Share by Application (2026-2031)
 Table 64. Global Human Recombinant Insulin Revenue (US$ Million) by Application (2020-2025)
 Table 65. Global Human Recombinant Insulin Revenue (US$ Million) by Application (2026-2031)
 Table 66. Global Human Recombinant Insulin Revenue Market Share by Application (2020-2025)
 Table 67. Global Human Recombinant Insulin Revenue Market Share by Application (2026-2031)
 Table 68. Global Human Recombinant Insulin Price (USD/Litre) by Application (2020-2025)
 Table 69. Global Human Recombinant Insulin Price (USD/Litre) by Application (2026-2031)
 Table 70. Novo Nordisk Company Information
 Table 71. Novo Nordisk Description and Business Overview
 Table 72. Novo Nordisk Human Recombinant Insulin Sales (K Litre), Revenue (US$ Million), Price (USD/Litre) and Gross Margin (2020-2025)
 Table 73. Novo Nordisk Human Recombinant Insulin Product
 Table 74. Novo Nordisk Recent Developments/Updates
 Table 75. Eli Lilly and Company Company Information
 Table 76. Eli Lilly and Company Description and Business Overview
 Table 77. Eli Lilly and Company Human Recombinant Insulin Sales (K Litre), Revenue (US$ Million), Price (USD/Litre) and Gross Margin (2020-2025)
 Table 78. Eli Lilly and Company Human Recombinant Insulin Product
 Table 79. Eli Lilly and Company Recent Developments/Updates
 Table 80. Sanofi Company Information
 Table 81. Sanofi Description and Business Overview
 Table 82. Sanofi Human Recombinant Insulin Sales (K Litre), Revenue (US$ Million), Price (USD/Litre) and Gross Margin (2020-2025)
 Table 83. Sanofi Human Recombinant Insulin Product
 Table 84. Sanofi Recent Developments/Updates
 Table 85. Julphar Gulf Pharmaceutical Industries Company Information
 Table 86. Julphar Gulf Pharmaceutical Industries Description and Business Overview
 Table 87. Julphar Gulf Pharmaceutical Industries Human Recombinant Insulin Sales (K Litre), Revenue (US$ Million), Price (USD/Litre) and Gross Margin (2020-2025)
 Table 88. Julphar Gulf Pharmaceutical Industries Human Recombinant Insulin Product
 Table 89. Julphar Gulf Pharmaceutical Industries Recent Developments/Updates
 Table 90. Bioton Company Information
 Table 91. Bioton Description and Business Overview
 Table 92. Bioton Human Recombinant Insulin Sales (K Litre), Revenue (US$ Million), Price (USD/Litre) and Gross Margin (2020-2025)
 Table 93. Bioton Human Recombinant Insulin Product
 Table 94. Bioton Recent Developments/Updates
 Table 95. Gan & Lee Pharmaceuticals Company Information
 Table 96. Gan & Lee Pharmaceuticals Description and Business Overview
 Table 97. Gan & Lee Pharmaceuticals Human Recombinant Insulin Sales (K Litre), Revenue (US$ Million), Price (USD/Litre) and Gross Margin (2020-2025)
 Table 98. Gan & Lee Pharmaceuticals Human Recombinant Insulin Product
 Table 99. Gan & Lee Pharmaceuticals Recent Developments/Updates
 Table 100. Zhuhai United Laboratories Company Information
 Table 101. Zhuhai United Laboratories Description and Business Overview
 Table 102. Zhuhai United Laboratories Human Recombinant Insulin Sales (K Litre), Revenue (US$ Million), Price (USD/Litre) and Gross Margin (2020-2025)
 Table 103. Zhuhai United Laboratories Human Recombinant Insulin Product
 Table 104. Zhuhai United Laboratories Recent Developments/Updates
 Table 105. Biocon Company Information
 Table 106. Biocon Description and Business Overview
 Table 107. Biocon Human Recombinant Insulin Sales (K Litre), Revenue (US$ Million), Price (USD/Litre) and Gross Margin (2020-2025)
 Table 108. Biocon Human Recombinant Insulin Product
 Table 109. Biocon Recent Developments/Updates
 Table 110. Wanbang Biopharmaceuticals Company Information
 Table 111. Wanbang Biopharmaceuticals Description and Business Overview
 Table 112. Wanbang Biopharmaceuticals Human Recombinant Insulin Sales (K Litre), Revenue (US$ Million), Price (USD/Litre) and Gross Margin (2020-2025)
 Table 113. Wanbang Biopharmaceuticals Human Recombinant Insulin Product
 Table 114. Wanbang Biopharmaceuticals Recent Developments/Updates
 Table 115. Dongbao Enterprise Group Company Information
 Table 116. Dongbao Enterprise Group Description and Business Overview
 Table 117. Dongbao Enterprise Group Human Recombinant Insulin Sales (K Litre), Revenue (US$ Million), Price (USD/Litre) and Gross Margin (2020-2025)
 Table 118. Dongbao Enterprise Group Human Recombinant Insulin Product
 Table 119. Dongbao Enterprise Group Recent Developments/Updates
 Table 120. PeproTech Company Information
 Table 121. PeproTech Description and Business Overview
 Table 122. PeproTech Human Recombinant Insulin Sales (K Litre), Revenue (US$ Million), Price (USD/Litre) and Gross Margin (2020-2025)
 Table 123. PeproTech Human Recombinant Insulin Product
 Table 124. PeproTech Recent Developments/Updates
 Table 125. Key Raw Materials Lists
 Table 126. Raw Materials Key Suppliers Lists
 Table 127. Human Recombinant Insulin Distributors List
 Table 128. Human Recombinant Insulin Customers List
 Table 129. Human Recombinant Insulin Market Trends
 Table 130. Human Recombinant Insulin Market Drivers
 Table 131. Human Recombinant Insulin Market Challenges
 Table 132. Human Recombinant Insulin Market Restraints
 Table 133. Research Programs/Design for This Report
 Table 134. Key Data Information from Secondary Sources
 Table 135. Key Data Information from Primary Sources
 Table 136. Authors List of This Report


List of Figures
 Figure 1. Product Picture of Human Recombinant Insulin
 Figure 2. Global Human Recombinant Insulin Market Value Comparison by Type (2020-2031) & (US$ Million)
 Figure 3. Global Human Recombinant Insulin Market Share by Type: 2024 & 2031
 Figure 4. Rapid-Acting Human Insulin Product Picture
 Figure 5. Regular (Short Acting) Insulin Product Picture
 Figure 6. NPH (Intermediate Acting) Insulin Product Picture
 Figure 7. Long-Acting Human Insulin Product Picture
 Figure 8. Premixed Human Insulins Insulin Product Picture
 Figure 9. Global Human Recombinant Insulin Market Value by Application (2020-2031) & (US$ Million)
 Figure 10. Global Human Recombinant Insulin Market Share by Application: 2024 & 2031
 Figure 11. Hospital
 Figure 12. Retail Pharmacy
 Figure 13. Online Pharmacies
 Figure 14. Other
 Figure 15. Global Human Recombinant Insulin Revenue, (US$ Million), 2020 VS 2024 VS 2031
 Figure 16. Global Human Recombinant Insulin Market Size (2020-2031) & (US$ Million)
 Figure 17. Global Human Recombinant Insulin Sales (2020-2031) & (K Litre)
 Figure 18. Global Human Recombinant Insulin Average Price (USD/Litre) & (2020-2031)
 Figure 19. Human Recombinant Insulin Report Years Considered
 Figure 20. Human Recombinant Insulin Sales Share by Manufacturers in 2024
 Figure 21. Global Human Recombinant Insulin Revenue Share by Manufacturers in 2024
 Figure 22. Global 5 and 10 Largest Human Recombinant Insulin Players: Market Share by Revenue in Human Recombinant Insulin in 2024
 Figure 23. Human Recombinant Insulin Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
 Figure 24. Global Human Recombinant Insulin Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Figure 25. North America Human Recombinant Insulin Sales Market Share by Country (2020-2031)
 Figure 26. North America Human Recombinant Insulin Revenue Market Share by Country (2020-2031)
 Figure 27. U.S. Human Recombinant Insulin Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 28. Canada Human Recombinant Insulin Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 29. Europe Human Recombinant Insulin Sales Market Share by Country (2020-2031)
 Figure 30. Europe Human Recombinant Insulin Revenue Market Share by Country (2020-2031)
 Figure 31. Germany Human Recombinant Insulin Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 32. France Human Recombinant Insulin Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 33. U.K. Human Recombinant Insulin Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 34. Italy Human Recombinant Insulin Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 35. Russia Human Recombinant Insulin Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 36. Asia Pacific Human Recombinant Insulin Sales Market Share by Region (2020-2031)
 Figure 37. Asia Pacific Human Recombinant Insulin Revenue Market Share by Region (2020-2031)
 Figure 38. China Human Recombinant Insulin Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 39. Japan Human Recombinant Insulin Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 40. South Korea Human Recombinant Insulin Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 41. India Human Recombinant Insulin Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 42. Australia Human Recombinant Insulin Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 43. Taiwan Human Recombinant Insulin Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 44. Indonesia Human Recombinant Insulin Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 45. Thailand Human Recombinant Insulin Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 46. Malaysia Human Recombinant Insulin Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 47. Philippines Human Recombinant Insulin Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 48. Latin America Human Recombinant Insulin Sales Market Share by Country (2020-2031)
 Figure 49. Latin America Human Recombinant Insulin Revenue Market Share by Country (2020-2031)
 Figure 50. Mexico Human Recombinant Insulin Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 51. Brazil Human Recombinant Insulin Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 52. Argentina Human Recombinant Insulin Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 53. Middle East and Africa Human Recombinant Insulin Sales Market Share by Country (2020-2031)
 Figure 54. Middle East and Africa Human Recombinant Insulin Revenue Market Share by Country (2020-2031)
 Figure 55. Turkey Human Recombinant Insulin Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 56. Saudi Arabia Human Recombinant Insulin Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 57. UAE Human Recombinant Insulin Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 58. Global Sales Market Share of Human Recombinant Insulin by Type (2020-2031)
 Figure 59. Global Revenue Market Share of Human Recombinant Insulin by Type (2020-2031)
 Figure 60. Global Human Recombinant Insulin Price (USD/Litre) by Type (2020-2031)
 Figure 61. Global Sales Market Share of Human Recombinant Insulin by Application (2020-2031)
 Figure 62. Global Revenue Market Share of Human Recombinant Insulin by Application (2020-2031)
 Figure 63. Global Human Recombinant Insulin Price (USD/Litre) by Application (2020-2031)
 Figure 64. Human Recombinant Insulin Value Chain
 Figure 65. Channels of Distribution (Direct Vs Distribution)
 Figure 66. Bottom-up and Top-down Approaches for This Report
 Figure 67. Data Triangulation
 Figure 68. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$2900

This license allows only one user to access the PDF.
Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)

OUR CUSTOMER

Strategic Venue Partners